Evidence map›Paper›PMID 41254158›Full record

ArticleCommunications medicine2025

Insights from pharmacovigilance databases, clinical cohorts and preclinical models into VEGF(R) inhibitor-induced arthritis in cancer.

Lan Xu, Anqi Lin, Zhengrui Li, Junyi Shen, Hao Chi, Hank Z H Wong, Jian Zhang, Qi Wang, Jianying Xu, Pengpeng Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Lan Xu *Donghai County People's Hospital (Affiliated Kangda College of Nanjing Medical University); Department of Oncology, Zhujiang Hospital, Southern Medical University, Lianyungang, China.
Anqi Lin *Donghai County People's Hospital (Affiliated Kangda College of Nanjing Medical University); Department of Oncology, Zhujiang Hospital, Southern Medical University, Lianyungang, China.
Zhengrui Li *Department of Oral and Cranio-Maxillofacial Surgery, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine, National Clinical Research Center for Oral Diseases, Shanghai Key Laboratory of Stomatology and Shanghai Research Institute of Stomatology, Shanghai, China.
Junyi Shen *Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Hao Chi *Department of Quantitative Health Sciences, John A. Burns School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA.
Hank Z H Wong *Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Jian ZhangDepartment of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.ORCID http://orcid.org/0000-0001-7217-0111
Qi WangDepartment of Oncology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. drwang71111@163.com.ORCID http://orcid.org/0000-0002-5287-6050
Jianying XuDepartment of Medicine II, LMU University Hospital, Munich, Germany. jianying.xu@med.uni-muenchen.de.ORCID http://orcid.org/0009-0007-1924-8400
Pengpeng ZhangDepartment of Lung Cancer, Tianjin Lung Cancer Center, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. zpp19940120@tmu.edu.cn.ORCID http://orcid.org/0009-0004-6951-2634
Peng LuoDonghai County People's Hospital (Affiliated Kangda College of Nanjing Medical University); Department of Oncology, Zhujiang Hospital, Southern Medical University, Lianyungang, China. luopeng@smu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundVEGF and VEGFR inhibitors are key in targeted therapy for various malignancies, but arthritis-related side effects are poorly understood. This study investigates the incidence, risk factors, and molecular mechanisms of VEGF(R) inhibitor-induced arthritis.

methodsStatistical analyses of VEGF(R) inhibitor-related arthritis adverse events were conducted using data from the Food and Drug Administration Adverse Event Reporting System (FAERS) and the World Health Organization's global individual case safety reports database (VigiBase), with risk assessment performed using reporting odds ratio (ROR) and proportional reporting ratio (PRR). The effects of VEGF(R)i treatment on arthritis-related biomarkers were validated through the analysis of clinical data from cancer patients receiving VEGF(R)i therapy. A VEGF(R)i-treated mouse model was established using only male mice to investigate transcriptomic changes in bone tissue using high-throughput sequencing technology, thereby exploring potential mechanisms of VEGF(R)i-related arthritis.

resultsFAERS and VigiBase data show a significant link between VEGF(R) inhibitors and arthritis, with a higher incidence in females and individuals under 65. Clinical data reveal elevated inflammatory markers post-treatment. Transcriptomic analysis shows the activation of some and suppression of other inflammation-related pathways in bone tissue after VEGF(R) inhibitor treatment.

conclusionsThis study provides a systematic analysis of VEGF(R) inhibitor-related arthritis, reveals its incidence patterns and potential molecular mechanisms, and offers insights into prevention and treatment strategies for this side effect in clinical practice.

Identifiers

PMID41254158
PMCPMC12627425

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.